Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease

Overview of attention for article published in Stem Cell Research & Therapy, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 2,792)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 32 news outlets

blogs: 1 blog

Readers on

mendeley: 27 Mendeley

Summary News Blogs

So far, Altmetric has seen 45 news stories from 32 outlets.

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

Kxan, 08 Nov 2022

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract entitled “Reduction of plasma…

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

KOIN 6, 08 Nov 2022

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract entitled “Reduction of plasma…

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

News Channel 11 wjhl.com, 08 Nov 2022

News provided by Neuronascent, Inc. Nov 08, 2022, 6:00 AM ET ROCKVILLE, Md., Nov.

News story from News Channel 8 on Tuesday 08 November 2022

News Channel 8 , 08 Nov 2022

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 41 additional news stories.